Journal of Clinical and Experimental Hematopathology
Online ISSN : 1880-9952
Print ISSN : 1346-4280
ISSN-L : 1346-4280
Original Article
Attenuated Antibody Reaction for the Primary Antigen but not for the Recall Antigen of Influenza Vaccination in Patients with Non-Hodgkin B-Cell Lymphoma after the Administration of Rituximab-CHOP
Tohru TakataJunji SuzumiyaTakahiko IshikawaYasushi TakamatsuHideyuki IkematsuKazuo Tamura
Author information
JOURNAL FREE ACCESS

2009 Volume 49 Issue 1 Pages 9-13

Details
Abstract

To assess the humoral response to the influenza vaccine in patients undergoing R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone) for non-Hodgkin lymphoma (NHL), the anti-hemagglutinin (HA) titer in 7 NHL patients undergoing therapy was compared with those in 10 control group subjects in the 2005/2006 season. Four weeks after vaccination, the HA titers against the influenza type A H1N1 and type B antigens, the same antigens that had been used in the previous seasons, were elevated in all patients treated with R-CHOP. In contrast, there was no increase in the geometric mean titer for type A H3N2 antigen, which was newly included in 2005/2006 season, in the patients treated with R-CHOP, while there was a significant increase in the 10 control subjects (p = 0.014). This study showed that vaccination against influenza virus generated an appreciable humoral response to recall antigens in NHL patients treated with R-CHOP therapy, but not to the primary antigen. [J Clin Exp Hematopathol 49(1) : 9-13, 2009]

Content from these authors
© 2009 by The Japanese Society for Lymphoreticular Tissue Research
Previous article Next article
feedback
Top